370,300 Shares in R1 RCM Inc. (NASDAQ:RCM) Acquired by HBK Investments L P

HBK Investments L P purchased a new stake in R1 RCM Inc. (NASDAQ:RCM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 370,300 shares of the healthcare provider’s stock, valued at approximately $5,247,000.

Several other large investors have also recently bought and sold shares of RCM. Advisors Asset Management Inc. bought a new position in R1 RCM in the 1st quarter valued at $27,000. GAMMA Investing LLC lifted its holdings in shares of R1 RCM by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after acquiring an additional 759 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of R1 RCM by 589.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock worth $44,000 after acquiring an additional 2,669 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in shares of R1 RCM during the 2nd quarter worth $86,000. Finally, Values First Advisors Inc. bought a new stake in shares of R1 RCM during the 3rd quarter worth $88,000. 61.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on RCM shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 price objective on shares of R1 RCM in a report on Friday, October 4th. Leerink Partners downgraded shares of R1 RCM from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $17.00 to $14.30 in a report on Thursday, August 1st. Leerink Partnrs downgraded shares of R1 RCM from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley cut shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 8th. Finally, Truist Financial decreased their target price on shares of R1 RCM from $16.00 to $14.30 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Thirteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.41.

R1 RCM Price Performance

RCM stock opened at $14.31 on Friday. The firm’s 50-day moving average price is $14.24 and its two-hundred day moving average price is $13.51. R1 RCM Inc. has a 12-month low of $8.87 and a 12-month high of $15.12. The stock has a market capitalization of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.76.

R1 RCM (NASDAQ:RCM) last announced its earnings results on Tuesday, November 5th. The healthcare provider reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). The company had revenue of $656.80 million for the quarter, compared to the consensus estimate of $640.93 million. R1 RCM had a negative net margin of 2.48% and a negative return on equity of 2.18%. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. As a group, equities analysts predict that R1 RCM Inc. will post -0.18 earnings per share for the current year.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.